绞股蓝总甙治疗高血脂症合并脂肪肝的疗效观察

Clincal Efficacy of Lipid-lowering Drug in Hyperlipidemia with Fatty Liver:One Clincal Observation

目的通过常规护肝治疗与联合调脂药绞股蓝总甙治疗进行对比,了解绞股蓝总甙对高血脂症合并脂肪肝的临床疗效及安全性。方法随机将非酒精性脂肪肝门诊患者分为对照组54例,给予能量合剂及甘利欣静脉给药治疗;治疗组98例,在应用上述治疗的同时,给予绞股蓝总甙胶囊1粒,3次/d,口服。两组疗程均4周。结果对照组TC、TG、LDL-c及ALT、AST下降不明显,HDL-c无明显变化(P>0.05);治疗组TC、TG、LDL-c及ALT、AST、LDL-c显著降低,并提高了HDL-c水平(P<0.05)。经过4周治疗,治疗组患者TC、TG、ALT、AST明显降到目标水平,与对照组比较疗效有显著差异(P<0.01)。用药前后两组血糖、血尿素氮、血肌酐均无统计学差异。结论高血脂症合并脂肪肝、肝功能异常者,在常规护肝和同时,给予绞股蓝总甙治疗疗效好,可明显降低TC、TG、LDL-c,提高HDL-c,并促进ALT、AST恢复,且不会导致肾功能和血糖异常。

Objective To investigate the clinical efficacy and safety of Chinese lipid-lowering drug Jiaogulanzongdai combined with hepatic protection drugs on patients of non alcoholic hyperlipidemia with fatty liver.Methods There were no signficant difference two goups on total cholesterol,triglyceride,LDL-c,HDL-c,and liver function before treatment.54 patients in group A received the baseline treatment with energy mixture and diammonium glcyrrhiznate while 98 patients in group B received Jiaogulanzongdai combined with the baseline treatment,both groups were treated for four weeks.Results On the measurement of total cholesterol,triglyceride,LDL-c,HDL-c,liver function,there were no significant changes in group A after treatment（P0.05） while in group B,they were greatly reduced except that HDL-c was enhanced（P0.05）.There was a significant difference on efficacy between the two group（P0.01）.No changes on blood glucose and BUN,plasma creatine were found.Conclusion Treatmeat with lipid-lowering drug Jiaogulanzongdai could result in the decrease of lipid leve and improvement of hepatic function on hyperlipidemia with fatty liver patients without side effects on glucose metabolism and renal function were observed.